Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice-论文-万方医学网

首页> > Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice

Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice

导出原文传递

翻译打印收藏纠错

第一作者： Khanna, Dinesh

作者： Khanna, Dinesh ^[1] ; Lescoat, Alain ^[2] ; Roofeh, David ^[3] ; Bernstein, Elana J. ^[4] ; Kazerooni, Ella A. ^[5] ; Roth, Michael D. ; Martinez, Fernando ; Flaherty, Kevin R. ; Denton, Christopher P.

作者单位： Univ Michigan ^[1] Univ Calif Los Angeles ^[2] Irving Med Ctr,Columbia Univ ^[3] NYU ^[4] UCL ^[5]

关键词 PULMONARY ARTERIAL-HYPERTENSION DOUBLE-BLIND MYCOPHENOLATE-MOFETIL ORAL CYCLOPHOSPHAMIDE OPEN-LABEL FIBROSIS SURVIVAL SAFETY TRANSPLANTATION EFFICACY

发布时间 2022-05-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

法律状态公告日	法律状态	法律状态信息

检索历史清除

Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice

相似文献

同项目论文

相关期刊

检索历史 清除

Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice

相似文献

同项目论文

相关期刊

检索历史清除